Draghi2019 - Parameter identification of a model for prostate cancer treated by intermittent therapy

  public model
Model Identifier
MODEL1911100005
Short description
This is a mathematical describing the interaction between the prostate adenocarcinoma tumor environment, the prostate specific antigen (PSA) produced by hormone-dependent and hormone-independent tumor cells, respectively, and the level of androgens.
Format
SBML (L2V4)
Related Publication
  • Parameter identification of a model for prostate cancer treated by intermittent therapy.
  • Draghi C, Denis F, Tol├ędano A, Letellier C
  • Journal of theoretical biology , 1/ 2019 , Volume 461 , pages: 117-132 , PubMed ID: 30292801
  • Institut Rafael Centre de Recherche, 3 Boulevard Bineau, Levallois-Perret F-92300, France.
  • Adenocarcinoma is the most frequent cancer affecting the prostate walnut-size gland in the male reproductive system. Such cancer may have a very slow progression or may be associated with a "dark prognosis" when tumor cells are spreading very quickly. Prostate cancers have the particular properties to be marked by the level of prostate specific antigen (PSA) in blood which allows to follow its evolution. At least in its first phase, prostate adenocarcinoma is most often hormone-dependent and, consequently, hormone therapy is a possible treatment. Since few years, hormone therapy started to be provided intermittently for improving patient's quality of life. Today, durations of on- and off-treatment periods are still chosen empirically, most likely explaining why there is no clear benefit from the survival point of view. We therefore developed a model for describing the interaction between the tumor environment, the PSA produced by hormone-dependent and hormone-independent tumor cells, respectively, and the level of androgens. Model parameters were identified using a genetic algorithm applied to the PSA time series measured in a few patients who initially received prostatectomy and were then treated by intermittent hormone therapy (LHRH analogs and anti-androgen). The measured PSA time series is quite correctly reproduced by free runs over the whole follow-up. Model parameter values allow for distinguishing different types of patient (age and Gleason score) meaning that the model can be individualized. We thus showed that the long-term evolution of the cancer can be affected by durations of on- and off-treatment periods.
Contributors
Submitter of the first revision: Johannes Meyer
Submitter of this revision: Johannes Meyer
Modellers: Johannes Meyer

Metadata information

hasProperty (1 statement)
Mathematical Modelling Ontology Ordinary differential equation model


Curation status
Non-curated


Tags

Connected external resources

SBGN view in Newt Editor

Name Description Size Actions

Model files

Draghi2019.xml SBML L2V4 Representation of Draghi2019 - Parameter identification of a model for prostate cancer treated by intermittent therapy 45.34 KB Preview | Download

Additional files

Draghi2019.cps COPASI file of Draghi2019 - Parameter identification of a model for prostate cancer treated by intermittent therapy 87.00 KB Preview | Download

  • Model originally submitted by : Johannes Meyer
  • Submitted: Nov 10, 2019 10:10:35 PM
  • Last Modified: Nov 10, 2019 10:10:35 PM
Revisions
  • Version: 1 public model Download this version
    • Submitted on: Nov 10, 2019 10:10:35 PM
    • Submitted by: Johannes Meyer
    • With comment: Import of Draghi2019 - Parameter identification of a model for prostate cancer treated by intermittent therapy